Dashboard
High Management Efficiency with a high ROE of 19.09%
Company has a low Debt to Equity ratio (avg) at 0 times
The company has declared Positive results for the last 17 consecutive quarters
Stock is technically in a Mildly Bullish range
With ROE of 17.7, it has a Very Expensive valuation with a 4 Price to Book Value
Majority shareholders : Promoters
Stock DNA
Pharmaceuticals & Biotechnology
INR 15,611 Cr (Small Cap)
22.00
40
0.38%
-0.24
17.66%
4.10
Total Returns (Price + Dividend) 
Latest dividend: 3.987158559146806 per share ex-dividend date: Sep-18-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Caplin Point Laboratories Ltd is Rated Hold
Caplin Point Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 Oct 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Caplin Point Laboratories Ltd Hits Intraday Low Amid Price Pressure
Caplin Point Laboratories Ltd experienced a significant intraday decline on 18 Nov 2026, touching a low of Rs 2,073.5, down 7.89% from the previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure and heightened volatility.
Read More
Caplin Point Laboratories Ltd is Rated Hold
Caplin Point Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19-Nov-2026 | Source : BSETranscript for Earnings call - Q2 - FY 2026-27
Update On US FDA Inspection At The Facility Of Caplin Steriles Limited Subsidiary Of The Company
17-Nov-2026 | Source : BSEClassification of US FDA Inspection at the facility of Caplin Steriles Limited subsidiary of the Company as OAI
Board Meeting Outcome for Meeting Held On November 12 2026
12-Nov-2026 | Source : BSEBoard Meeting Outcome for Meeting Held on November 12 2026
Corporate Actions 
No Upcoming Board Meetings
Caplin Point Laboratories Ltd has declared 200% dividend, ex-date: 18 Sep 26
Caplin Point Laboratories Ltd has announced 2:10 stock split, ex-date: 19 Oct 16
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 20 Schemes (1.64%)
Held by 157 FIIs (5.73%)
P Vijayalakshmi (24.71%)
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs (2.81%)
14.94%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 17.94% vs 10.54% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 15.31% vs 18.08% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 10.85% vs 16.97% in Sep 2024
Growth in half year ended Sep 2025 is 20.60% vs 16.71% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 10.59% vs 15.65% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 19.66% vs 17.36% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 12.89% vs 14.37% in Mar 2025
YoY Growth in year ended Mar 2026 is 19.57% vs 17.33% in Mar 2025